Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
(MOUNTAIN Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression.The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.
Who Is on the Research Team?
Joyce S Lee
Principal Investigator
University of Colorado, Denver
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Initial collection of blood samples, buccal swabs, questionnaires, and clinical tests including HRCT scans and pulmonary function tests if performed clinically
Ongoing Monitoring
Every 4 months, blood samples and questionnaires are collected at clinic visits
Annual Follow-up
Annual collection of blood samples, buccal swabs, questionnaires, and clinical tests including HRCT scans and pulmonary function tests if performed clinically
Long-term Follow-up
Participants are monitored for disease progression and survival status through questionnaires and medical chart review
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
University of Michigan
Collaborator
University of California, San Francisco
Collaborator
University of Kansas
Collaborator